Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/23/22 → 5/31/29 |
Funding
- Novartis (domestic): $264,212.00
22-LUN-129-NP-PMC: CAAA601A42101, A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Tislelizumab in Inducti
- Hao, Zhonglin (PI)
- Chauhan, Aman (Former PI)